Results 1 to 10 of about 395 (108)

Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages

BMC Cancer, 2023
Purpose The combined application of immune checkpoint inhibitors (ICIs) and anti-angiogenesis therapy has shown synergistic effects on glioblastoma (GBM).
Xin Liu, Zhenke Li, Jinxing Sun, Zhijie Zhang, Weiguo Li   +4 more
doaj   +3 more sources

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Background Trans-acting programmed death-ligand 1 (PD-L1) derives from malignant cells in three known forms. High levels of secreted splice variant PD-L1 (sPD-L1), ADAM10/ADAM17-shed sPD-L1, and PD-L1-positive extracellular vesicles (evPD-L1) each ...
Haidong Dong, Svetomir N Markovic, Aaron S Mansfield, Jacob J Orme, Elizabeth Ann L Enninga, Fabrice Lucien-Matteoni, Heather Dale, Edwin Burgstaler, Susan M Harrington, Matthew K Ball, Sean S Park, Mathew S Block, Yiyi Yan, Roxana S Dronca, Jeffrey L Winters   +14 more
doaj   +3 more sources

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer

Frontiers in Immunology, 2022
The immune checkpoint pathway consisting of the cell membrane-bound molecule programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate negative regulatory signals that effectively inhibit T-cell proliferation and function and ...
Mengke Niu, Yiming Liu, Ming Yi, Dechao Jiao, Kongming Wu, Kongming Wu   +5 more
doaj   +5 more sources

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma [PDF]

Microorganisms, 2021
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated malignancy. The principal oncogene of EBV, latent membrane protein 1 (LMP1), induces the expression of programmed death-ligand 1 (PD-L1), which is an immunosuppressive transmembrane
Kina Kase, Satoru Kondo, Naohiro Wakisaka, Hirotomo Dochi, Harue Mizokami, Eiji Kobayashi, Makoto Kano, Takeshi Komori, Nobuyuki Hirai, Takayoshi Ueno, Yosuke Nakanishi, Miyako Hatano, Kazuhira Endo, Makiko Moriyama-Kita, Hisashi Sugimoto, Tomokazu Yoshizaki   +15 more
doaj   +3 more sources

Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients [PDF]

Diagnostics, 2022
CD163+ M2 macrophages have been suggested to counteract tumor immunity by increasing immunosuppressive mechanisms including PD-L1 and IL-10 expression.
Sabina Davidsson, Sofia Huotilainen, Jessica Carlsson, Pernilla Sundqvist   +3 more
doaj   +3 more sources

Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist

eLife, 2019
Immune regulation is a finely balanced process of positive and negative signals. PD-L1 and its receptor PD-1 are critical regulators of autoimmune, antiviral and antitumoural T cell responses.
Kevin W Ng, Jan Attig, George R Young, Eleonora Ottina, Spyros I Papamichos, Ioannis Kotsianidis, George Kassiotis   +6 more
doaj   +3 more sources

PD-L1 Gene Polymorphism and High Level of Plasma Soluble Pd-L1 Protein may be aSsociated with Non-Small Cell Lung Cancer

The International Journal of Biological Markers, 2015
Background PD-1 and its ligand PD-L1 belong to the co-inhibition molecules, which can downregulate immune responses. The PD-L1 polymorphism and the level of soluble PD-L1 (sPD-L1) were investigated in non-small cell lung cancer (NSCLC).
Sensen Cheng, Jinsong Zheng, Jingyan Zhu, Chao Xie, Xia Zhang, Xiao Han, Bao Song, Yuan Ma, Jie Liu   +8 more
doaj   +3 more sources

Soluble PD-L1 as an early marker of progressive disease on nivolumab [PDF]

Journal for ImmunoTherapy of Cancer, 2022
Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC) and melanoma patients, and investigated its relationship to ...
Kathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, Linan Song, Eliseo Veras, Megan Wind-Rotolo, David F McDermott, F Stephen Hodi, Toni K Choueiri, Gordon J Freeman   +9 more
openaire   +3 more sources

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression

Frontiers in Immunology, 2023
BackgroundNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes ...
Afsheen Raza, Afsheen Raza, Reyad Mohsen, Aladdin Kanbour, Abdul Rehman Zar Gul, Anite Philip, Suma Vijayakumar, Shereena Hydrose, Shereena Hydrose, Kirti S. Prabhu, Aisha Khamis Al-Suwaidi, Aisha Khamis Al-Suwaidi, Varghese Philipose Inchakalody, Varghese Philipose Inchakalody, Maysaloun Merhi, Maysaloun Merhi, Dina M. Abo El-Ella, Dina M. Abo El-Ella, Melissa Annrose Tauro, Shayista Akbar, Issam Al-Bozom, Wafa Abualainin, Rajaa Al-Abdulla, Shaza Abu Sirriya, Suparna Hassnad, Shahab Uddin, Shahab Uddin, Mohamed Izham Mohamed Ibrahim, Ussama Al Homsi, Said Demime, Said Demime, Said Demime   +31 more
doaj   +1 more source

Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients [PDF]

Cancers, 2021
Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria ...
Anders Vikerfors, Sabina Davidsson, Janusz Frey, Tomas Jerlström, Jessica Carlsson   +4 more
openaire   +2 more sources